Inhibikase Therapeutics, Inc. (IKT) Stock Forecast & Price Target

Inhibikase Therapeutics, Inc. (IKT) has an ST Score of 64.9 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate IKT a Hold, with a price target of $4.83 (+182.5% vs the current price). Our ST Score grades it B (64.9/100). The ST Score is a data-driven signal, not a recommendation.

Valuation A, Profitability B-, Financial Strength A+, Momentum B+, Growth C, Forecast A.

Inhibikase Therapeutics, Inc. (IKT) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Inhibikase Therapeutics, Inc. (IKT) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Inhibikase Therapeutics, Inc. (IKT) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Inhibikase Therapeutics, Inc. (IKT) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Inhibikase Therapeutics, Inc. (IKT) is $4.83 from 2 analysts, which is +182.5% versus the recent price of $1.71.

Inhibikase Therapeutics, Inc. (IKT) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.